ArticleEuropean journal of nuclear medicine and molecular imaging2026
Patient selection for PRRT rechallenge in neuroendocrine tumors: impact of initial response duration on outcomes.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatient selection for rechallenge peptide receptor radionuclide therapy (re-PRRT) in neuroendocrine tumors (NET) remains poorly defined. As re-PRRT is increasingly considered in clinical practice, identifying patients most likely to benefit has become a critical yet unresolved question. This study evaluated the efficacy and safety of re-PRRT and aimed to identify pragmatic factors associated with retreatment benefit. MATERIALS AND
methodsThis retrospective study included 37 patients with neuroendocrine tumors (NET). Kaplan-Meier estimates were used to evaluate progression-free survival (PFS) following initial (i-PRRT) and re-PRRT. Baseline laboratory parameters were compared between treatment courses, and SSTR-targeted PET metrics (SUV
resultsMedian PFS was 32 months after i-PRRT and 17 months after re-PRRT, with disease progression observed in 20/37 patients. Longer PFS following initial therapy was associated with improved outcome after retreatment (per month, HR 0.96, 95% CI 0.93-0.999; p < 0.05). In an exploratory analysis, patients with an initial PFS exceeding 24 months demonstrated a longer median PFS after re-PRRT than those with shorter initial PFS (19 vs. 4 months; log-rank p = 0.02). Higher baseline CRP was significantly associated with shorter PFS after i-PRRT (per mg/dl, HR 8.8, 95% CI 1.2-58.6; p < 0.05), whereas no such association was observed for re-PRRT (per mg/dl, HR 0.79, 95% CI 0.13-3.8; p = 0.8). Instead, higher baseline LDH was significantly associated with shorter PFS following re-PRRT (per U/l, HR 1.007, 95% CI 1.000-1.014; p < 0.05). No PET-derived baseline parameter correlated with PFS. RECIST indicated predominantly stable disease across treatment courses, although responses were less favorable at retreatment. No grade ≥ 3 toxicities were observed during re-PRRT.
conclusionRe-PRRT represents a feasible treatment option for selected NET patients. Duration of disease control following initial PRRT was associated with outcome after re-PRRT and may represent a clinically relevant marker for patient selection. The exploratory 24-month threshold requires prospective validation before clinical implementation.
Indexed as
Identifiers
42595802What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.